|
135
|
Safety Signal of Erenumab and the Risk of Raynaud’s Phenomenon
|
|
Signal
|
|
|
134
|
Safety Signal of Isotretinoin and the Risk of Blood Growth Hormone Decrease (BGHD)
|
|
Signal
|
|
|
133
|
Safety Signal of Mycophenolic Acid and the Risk of Posterior Reversible Encephalopathy Syndrome (PRES)
|
|
Signal
|
|
|
132
|
Safety Signal of Zoster Vaccine and the Risk of Stevens-Johnson syndrome
|
|
Signal
|
|
|
131
|
Safety Signal of Olanzapine and the Risk of Congestive Cardiomyopathy
|
|
Signal
|
|
|
130
|
Safety Signal of Duloxetine and the Risk of Hepatic Necrosis
|
|
Signal
|
|
|
129
|
Safety Signal of Tetanus Toxoid (TT) Vaccine and Risk of Cellulitis
|
|
Signal
|
|
|
128
|
Safety Signal of Olmesartan and Risk of Drug Induced Liver Injury
|
|
Signal
|
|
|
127
|
Safety Signal of Everolimus and Risk of Osteonecrosis of Jaw
|
|
Signal
|
|
|
126
|
Safety Signal of Docetaxel and Risk of Rhabdomyolysis
|
|
Signal
|
|
